C-reactive protein (CRP) is not a mere marker, but an active pathogenic substance

Circulation Journal

Volumn 75, Issue 7, 2011, Pages 1579-1580

  Miura, Toshiro ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CELL PROTEIN; FC RECEPTOR; FC RECEPTOR IIA; INTERLEUKIN 6; PROTEIN P47PHOX; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ATHEROGENESIS; ATHEROSCLEROSIS; CALCIUM METABOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL DAMAGE; CYTOKINE RELEASE; DIABETIC CARDIOMYOPATHY; DRUG TARGETING; EDITORIAL; HEART FAILURE; HUMAN; INFLAMMATORY INFILTRATE; LIGAND BINDING; MYOCARDIAL DISEASE; NONHUMAN; OXIDATIVE STRESS; PHAGOCYTOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RISK ASSESSMENT; SARCOPLASMIC RETICULUM; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; TRANSGENIC MOUSE;

ANIMALS; C-REACTIVE PROTEIN; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; HUMANS; MALE; MYOCARDIUM; VENTRICULAR REMODELING;

EID: 79959720829     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-0528     Document Type: Editorial

References (13)

1. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994; 331: 417-424.
2. Hurlimann J, Thorbecke GJ, Hochwald GM. The liver as the site of C-reactive protein formation. J Exp Med 1966; 123: 365-378.
3. Marnell L, Mold C, Du Clos TW. C-reactive protein: Ligands, receptors and role of inflammation. Clin Immunol 2005; 117: 104-111.
4. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-1565.
5. Scirica BM, Morrow DA. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation 2006; 113: 2128-2134.
6. Verma S, Devaraj S, Jialal I. C-reactive protein promotes atherosclerosis. Circulation 2006; 113: 2135-2150.
7. Xing D, Hage FG, Chen YF, McCrory MA, Feng W, Skibinski GA, et al. Exaggerated neointima formation in human C-reactive protein transgenic mice is IgG Fc receptor type I (Fc gamma RI)-dependent. Am J Pathol 2008; 172: 22-30.
8. Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, et al. C-reactive protein in heart failure: Prognostic value and the effect of valsartan. Circulation 2005; 112: 1428-1434.
9. Mano Y, Anzai T, Kaneko H, Nagatomo Y, Nagai T, Anzai A, et al. Overexpression of human C-reactive protein exacerbates left ventricular remodeling in diabetic cardiomyopathy. Circ J 2011; 75: 1717-1727.
10. Qin F, Simeone M, Patel R. Inhibition of NADPH oxidase reduces myocardial oxidative stress and apoptosis and improves cardiac function in heart failure after myocardial infarction. Free Radic Biol Med 2007; 43: 271-281.
11. Van Linthout S, Riad A, Dhayat N, Spillmann F, Du J, Dhayat S, et al. Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy. Diabetologia 2007; 50: 1977-1986.
12. Tron K, Manolov DE, Rocker C, Kachele M, Torzewski J, Nienhaus GU. C-reactive protein specifically binds to Fcgamma receptor type I on a macrophage-like cell line. Eur J Immunol 2008; 38: 1414-1422.
13. Windram JD, Loh PH, Rigby AS, Hanning I, Clark AL, Cleland JG. Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure. Am Heart J 2007; 153: 1048-1055.